Nantes, France, December 20, 2010 – TcLand Expression SA, a leading company focused on
Personalized Medicine today announced the appointment of Peter Payne as its Chief Business Officer
and head of US Operations.
TcLand Expression is developing breakthrough personalized medicine companion diagnostics in
immune mediated disorders and is clinically validating personalized medicine biomarkers for tolerance
in liver transplantation.
“We are particularly happy to welcome Peter Payne to TcLand Expression. Peter is a senior executive
with rare and extensive international experience in business operations and deal making in Europe
and in the USA. His arrival will significantly accelerate the potential of the company to enter into
major strategic industrial partnerships and corporate alliances, and leverage the value of the
company’s disruptive technologies”, said TcLand Expression CEO Alain Huriez, MD.
“I’m delighted to be joining the TcLand team at this time”, commented Peter Payne. “The company
has made significant progress since its inception and is now well poised to have considerable impact
on patient outcomes and stakeholder value. This is an exciting time for TcLand and I am looking
forward to being a part of the next phase of the company’s development”, added Peter.
Peter Payne, 51, joins TcLand Expression following a distinguished career within Quintiles
Transnational Corp where he held a variety of senior operational and Business Development positions
in Europe and the USA: he was latterly Vice President Corporate Development and responsible for the
development of relationships at a strategic level with a portfolio of biopharmaceutical companies,
Venture Capital funds, and other financial institutions. Peter’s experience in directing in-depth
portfolio analysis to create proactive development and commercialization strategies enabled him to
propose innovative business models and customized solutions to help biopharma companies manage
risk. Early on in his career, Peter also held roles at Wellcome Research Labs, Sterling Drug and Glaxo
Group Research, all based in the UK. Peter holds an Honors Degree in Pharmacology from the
University of Manchester and has completed post-graduate training at the University of North
Carolina and the University of Chicago Graduate School of Business.
TcLand Expression is an acknowledged pioneer in the discovery, the development and the validation of gene expression
biomarkers for unmet medical needs in transplantation and auto-immune disease. The company benefits from an exceptional scientific and clinical environment. For more information, please visit our website: www.tcland-expression.com
Alain Huriez, CEO Caroline Carmagnol
TcLand Expression ALIZE RP
Phone: +33 2 40 35 89 99 + 33 6 64 18 99 59